EMA's Updated Guidance On Monitoring Off-Label Use Of Medicines Expected By Year End
This article was originally published in SRA
Executive Summary
The European Medicines Agency is expected to finalize by the end of this year revisions to its policy on how drug companies should record and report off-label use of medicines not associated with an adverse reaction.